There is no consensus on how to follow patients with CLL and, in fact, no specific recommendations have been made by the NCI-WG,1 the IWCLL,2 or in some more recent guidelines.4142 Follow-up must be individualized on the basis of the characteristics of the patient and the disease. Patients with low-risk disease do not need to be monitored as frequently as those with poor prognostic features. Thus, patients with low-risk, stable disease may be evaluated every 6-12 months, whereas those with high-risk disease need to be seen at shorter intervals, e.g., every 3 months. Attention must be paid to the appearance of signs of disease progression or complications such as those discussed above, including disease transformation, second neoplasias, autoimmune phenomena, hypogammaglobulinemia, or infections.

0 0

Post a comment